世界の悪性神経膠腫治療薬市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV12579)
◆英語タイトル:Global Malignant Glioma Drugs Market Size, Status and Forecast 2020-2026
◆商品コード:QYR20NV12579
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2024年版があります。お問い合わせください。)
◆ページ数:98
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートは悪性神経膠腫治療薬の世界市場について調査・分析した資料です。種類別(アルキル化剤、VEGF/VEGFR阻害剤、抗血管新生薬)の市場規模、用途別(病院、がん研究機関、診断センター、その他)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別悪性神経膠腫治療薬の競争状況、市場シェア
・世界の悪性神経膠腫治療薬市場:種類別市場規模 2015年-2020年(アルキル化剤、VEGF/VEGFR阻害剤、抗血管新生薬)
・世界の悪性神経膠腫治療薬市場:種類別市場規模予測 2021年-2026年(アルキル化剤、VEGF/VEGFR阻害剤、抗血管新生薬)
・世界の悪性神経膠腫治療薬市場:用途別市場規模 2015年-2020年(病院、がん研究機関、診断センター、その他)
・世界の悪性神経膠腫治療薬市場:用途別市場規模予測 2021年-2026年(病院、がん研究機関、診断センター、その他)
・北米の悪性神経膠腫治療薬市場分析:米国、カナダ
・ヨーロッパの悪性神経膠腫治療薬市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの悪性神経膠腫治療薬市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の悪性神経膠腫治療薬市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの悪性神経膠腫治療薬市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Merck、Eli Lilly、AbbVie、Bristol-Myers Squibb、Genentech、Sun Pharmaceutical、BioMimetix、Cipla、Sigma-Aldrich、Panacea Biotec、Zydus Cadila
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Malignant glioma’s are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers.
In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and prevalence cases, followed by Europe where the major pharmaceuticals have their blockbuster drugs and include the major funding associations.

Market Analysis and Insights: Global Malignant Glioma Drugs Market
The global Malignant Glioma Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Malignant Glioma Drugs Scope and Market Size
Malignant Glioma Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Malignant Glioma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Merck
Eli Lilly
AbbVie
Bristol-Myers Squibb
Genentech
Sun Pharmaceutical
BioMimetix
Cipla
Sigma-Aldrich
Panacea Biotec
Zydus Cadila

Market segment by Type, the product can be split into
Alkylating Agents
VEGF/VEGFR Inhibitors
Anti Angiogenic Drugs
Market segment by Application, split into
Hospitals
Cancer Research Organizations
Diagnostic Centers
Other

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Malignant Glioma Drugs Revenue
1.4 Market by Type
1.4.1 Global Malignant Glioma Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Alkylating Agents
1.4.3 VEGF/VEGFR Inhibitors
1.4.4 Anti Angiogenic Drugs
1.5 Market by Application
1.5.1 Global Malignant Glioma Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Cancer Research Organizations
1.5.4 Diagnostic Centers
1.5.5 Other
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Malignant Glioma Drugs Market Perspective (2015-2026)
2.2 Global Malignant Glioma Drugs Growth Trends by Regions
2.2.1 Malignant Glioma Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Malignant Glioma Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Malignant Glioma Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Malignant Glioma Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Malignant Glioma Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Malignant Glioma Drugs Players by Market Size
3.1.1 Global Top Malignant Glioma Drugs Players by Revenue (2015-2020)
3.1.2 Global Malignant Glioma Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Malignant Glioma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Malignant Glioma Drugs Market Concentration Ratio
3.2.1 Global Malignant Glioma Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Malignant Glioma Drugs Revenue in 2019
3.3 Malignant Glioma Drugs Key Players Head office and Area Served
3.4 Key Players Malignant Glioma Drugs Product Solution and Service
3.5 Date of Enter into Malignant Glioma Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Malignant Glioma Drugs Historic Market Size by Type (2015-2020)
4.2 Global Malignant Glioma Drugs Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Malignant Glioma Drugs Market Size by Application (2015-2020)
5.2 Global Malignant Glioma Drugs Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Malignant Glioma Drugs Market Size (2015-2020)
6.2 Malignant Glioma Drugs Key Players in North America (2019-2020)
6.3 North America Malignant Glioma Drugs Market Size by Type (2015-2020)
6.4 North America Malignant Glioma Drugs Market Size by Application (2015-2020)

7 Europe
7.1 Europe Malignant Glioma Drugs Market Size (2015-2020)
7.2 Malignant Glioma Drugs Key Players in Europe (2019-2020)
7.3 Europe Malignant Glioma Drugs Market Size by Type (2015-2020)
7.4 Europe Malignant Glioma Drugs Market Size by Application (2015-2020)

8 China
8.1 China Malignant Glioma Drugs Market Size (2015-2020)
8.2 Malignant Glioma Drugs Key Players in China (2019-2020)
8.3 China Malignant Glioma Drugs Market Size by Type (2015-2020)
8.4 China Malignant Glioma Drugs Market Size by Application (2015-2020)

9 Japan
9.1 Japan Malignant Glioma Drugs Market Size (2015-2020)
9.2 Malignant Glioma Drugs Key Players in Japan (2019-2020)
9.3 Japan Malignant Glioma Drugs Market Size by Type (2015-2020)
9.4 Japan Malignant Glioma Drugs Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Malignant Glioma Drugs Market Size (2015-2020)
10.2 Malignant Glioma Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Malignant Glioma Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Malignant Glioma Drugs Market Size by Application (2015-2020)

11 India
11.1 India Malignant Glioma Drugs Market Size (2015-2020)
11.2 Malignant Glioma Drugs Key Players in India (2019-2020)
11.3 India Malignant Glioma Drugs Market Size by Type (2015-2020)
11.4 India Malignant Glioma Drugs Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Malignant Glioma Drugs Market Size (2015-2020)
12.2 Malignant Glioma Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Malignant Glioma Drugs Market Size by Type (2015-2020)
12.4 Central & South America Malignant Glioma Drugs Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Merck
13.1.1 Merck Company Details
13.1.2 Merck Business Overview
13.1.3 Merck Malignant Glioma Drugs Introduction
13.1.4 Merck Revenue in Malignant Glioma Drugs Business (2015-2020))
13.1.5 Merck Recent Development
13.2 Eli Lilly
13.2.1 Eli Lilly Company Details
13.2.2 Eli Lilly Business Overview
13.2.3 Eli Lilly Malignant Glioma Drugs Introduction
13.2.4 Eli Lilly Revenue in Malignant Glioma Drugs Business (2015-2020)
13.2.5 Eli Lilly Recent Development
13.3 AbbVie
13.3.1 AbbVie Company Details
13.3.2 AbbVie Business Overview
13.3.3 AbbVie Malignant Glioma Drugs Introduction
13.3.4 AbbVie Revenue in Malignant Glioma Drugs Business (2015-2020)
13.3.5 AbbVie Recent Development
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Company Details
13.4.2 Bristol-Myers Squibb Business Overview
13.4.3 Bristol-Myers Squibb Malignant Glioma Drugs Introduction
13.4.4 Bristol-Myers Squibb Revenue in Malignant Glioma Drugs Business (2015-2020)
13.4.5 Bristol-Myers Squibb Recent Development
13.5 Genentech
13.5.1 Genentech Company Details
13.5.2 Genentech Business Overview
13.5.3 Genentech Malignant Glioma Drugs Introduction
13.5.4 Genentech Revenue in Malignant Glioma Drugs Business (2015-2020)
13.5.5 Genentech Recent Development
13.6 Sun Pharmaceutical
13.6.1 Sun Pharmaceutical Company Details
13.6.2 Sun Pharmaceutical Business Overview
13.6.3 Sun Pharmaceutical Malignant Glioma Drugs Introduction
13.6.4 Sun Pharmaceutical Revenue in Malignant Glioma Drugs Business (2015-2020)
13.6.5 Sun Pharmaceutical Recent Development
13.7 BioMimetix
13.7.1 BioMimetix Company Details
13.7.2 BioMimetix Business Overview
13.7.3 BioMimetix Malignant Glioma Drugs Introduction
13.7.4 BioMimetix Revenue in Malignant Glioma Drugs Business (2015-2020)
13.7.5 BioMimetix Recent Development
13.8 Cipla
13.8.1 Cipla Company Details
13.8.2 Cipla Business Overview
13.8.3 Cipla Malignant Glioma Drugs Introduction
13.8.4 Cipla Revenue in Malignant Glioma Drugs Business (2015-2020)
13.8.5 Cipla Recent Development
13.9 Sigma-Aldrich
13.9.1 Sigma-Aldrich Company Details
13.9.2 Sigma-Aldrich Business Overview
13.9.3 Sigma-Aldrich Malignant Glioma Drugs Introduction
13.9.4 Sigma-Aldrich Revenue in Malignant Glioma Drugs Business (2015-2020)
13.9.5 Sigma-Aldrich Recent Development
13.10 Panacea Biotec
13.10.1 Panacea Biotec Company Details
13.10.2 Panacea Biotec Business Overview
13.10.3 Panacea Biotec Malignant Glioma Drugs Introduction
13.10.4 Panacea Biotec Revenue in Malignant Glioma Drugs Business (2015-2020)
13.10.5 Panacea Biotec Recent Development
13.11 Zydus Cadila
10.11.1 Zydus Cadila Company Details
10.11.2 Zydus Cadila Business Overview
10.11.3 Zydus Cadila Malignant Glioma Drugs Introduction
10.11.4 Zydus Cadila Revenue in Malignant Glioma Drugs Business (2015-2020)
10.11.5 Zydus Cadila Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

...

【掲載企業】

Merck、Eli Lilly、AbbVie、Bristol-Myers Squibb、Genentech、Sun Pharmaceutical、BioMimetix、Cipla、Sigma-Aldrich、Panacea Biotec、Zydus Cadila

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の悪性神経膠腫治療薬市場2026:インサイト・予測(Global Malignant Glioma Drugs Market Size, Status and Forecast 2020-2026)]についてメールでお問い合わせはこちらでお願いします。